Advances in the field of COX-2 inhibition

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 7, 2002, Pages 969-989

  de Leval, Xavier ^a   Julémont, Fabien ^a   Delarge, Jacques ^a   Sanna, Vanna ^a   Pirotte, Bernard ^a   Dogné, Jean Michel ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Arachidonic acid metabolism; Cancer; COX 2 selective inhibitors; Cyclooxygenases; Inflammation

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLENE DERIVATIVE; AZULENE DERIVATIVE; BENZENE DERIVATIVE; BENZOPYRAN DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; FURANONE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; INDOMETACIN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; OXAZOLONE; PHENYLBUTAZONE; PROSTANOID; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIDAZINONE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; PYRROLIZINE DERIVATIVE; ROFECOXIB; SELENIUM; THIADIAZOLE DERIVATIVE; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; BIOSYNTHESIS; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HOMEOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; PATENT; PATHOLOGY; PROTEIN EXPRESSION; REVIEW; SENSITIVITY ANALYSIS;

EID: 0036319155     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.7.969     Document Type: Review

References (104)

1. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase
2. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment
3. Cyclooxygenase-1 participates in selected vasodilator responses of the cerebral circulation
4. Interactions of PGH synthase isozymes-1 and -2 with NSAIDs
5. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic
6. Role of cyclooxygenase isoforms in gastric mucosal defence
7. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function
8. Distribution of COX-1 and COX-2 in normal and inflamed tissues
9. Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal antiinflammatory drug-related nephrotoxicity
10. COX-1 and COX-2 tissue expression: Implications and predictions
11. Prostaglandins in the stomach: An update
12. Cyclooxygenases 1 and 2
13. Pathogenesis of NSAID-induced gastroduodenal mucosal injury
14. Involvement of tyrosine kinases on cyclooxygenase expression and prostaglandin E2 production in human gingival fibroblasts stimulated with interleukin-1 beta and epidermal growth factor
15. Cyclooxygenases: Structural, cellular, and molecular biology
16. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids
17. Regulation of COX-2 expression in human intestinal myofibroblasts: Mechanisms of IL-1-mediated induction
18. Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2 in brain endothelial cells and also upregulate their receptors
19. Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity
20. Brucella lipopolysaccharides induce cyclooxygenase-2 expression in monocytic cells
21. Lipopolysaccharide-induced increase of prostaglandin E(2) is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase
22. Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo
23. Cyclooxygenase-2 in the spinal cord: Localization and regulation after a peripheral inflammatory stimulus
24. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells
25. Cyclooxygenase-2 as a therapeutic target
26. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer
27. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
28. Overexpression of cyclooxygenase 2 in squamous cell carcinoma of the hypopharynx
29. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ
30. Aromatase and COX-2 expression in human breast cancers
31. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer
32. Inhibition of cyclooxygenase-2: An approach to preventing cancer of the upper aerodigestive tract
33. COX-2 and colon cancer
34. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps
35. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas
36. Cyclooxygenase-2 expression in thyroid nodules
37. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia
38. Nonsteroidal anti-inflammatory drugs, apoptosis and colon cancer chemoprevention
39. COX-2 inhibition in clinical cancer prevention
40. Approach to angiogenesis inhibition based on cyclooxygenase-2
41. Role of cyclooxygenases in angiogenesis
42. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex
43. Mucosal defense and repair. Role of prostaglandins in the stomach and duodenum
44. Cox-2-selective inhibitors: The new super aspirins
45. Arachidonic acid metabolism
46. The effects of prostacyclin (PGI2) on tissues which detect prostaglandins (PG'S)
47. New trends in thromboxane and prostacyclin modulators
48. Prostaglandins; their biological and pharmacological role
49. Prostaglandins and oxytocin: Their effects on uterine smooth muscle
50. Renal prostaglandins, kidney function and essential hypertension
51. Mechanisms of pressure natriuresis
52. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene
53. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2
54. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme
55. Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and 5′-flanking regulatory sequences
56. Primary response genes induced by growth factors and tumor promoters
57. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2
58. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
59. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation
60. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase
61. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB
62. Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: Suppression by glucocorticoids and NSAIDs
63. Tumor necrosis factor-α promotes sustained cyclooxygenase-2 expression: Attenuation by dexamethasone and NSAIDs
64. Genetic conservation of cyclo-oxygenase
65. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
66. The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum
67. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells
68. The cyclooxygenase-2 structure: New drugs for an old target?
69. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase
70. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
71. Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach
72. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
73. Changes in the expression of the type-2 but not the type-1 cyclo-oxygenase enzyme in chorion-decidua with the onset of labour
74. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
75. Closing in on a stomach-sparing aspirin substitute
76. Evaluation of potential antirheumatic drugs in vitro using lymphocytes and epithelial cells. The selective action of indoxole, methyl glyoxal and chloroquine
77. Correlation of serum indoxole [2,3-bis(p-methoxyphenyl)-indole] levels with biologic activity
78. Anti-inflammatory activity of a non-steroidal anti-inflammatory agent, oxaprozin, in experimental models
79. Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives
80. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib)
81. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
82. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo
83. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
84. Celecoxib versus diclofenac in the management of osteoarthritis of the knee
85. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults
86. Celecoxib as adjunctive therapy for treatment of colorectal cancer
87. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2
88. Rofecoxib: Clinical pharmacology and clinical experience
89. Rofecoxib: A review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis
90. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors
91. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioidsparing analgesic in patients undergoing hip arthroplasty
92. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery
93. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2
94. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo
95. Multiple female reproductive failures in cyclooxygenase 2-deficient mice
96. Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells
97. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development
98. Physiological regulation of cyclooxygenase-2 in the kidney
99. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis
100. Characterization of inducible cyclooxygenase in rat brain
101. Activation of NFκB is necessary for IL-1β-induced cyclooxygenase-2 (COX-2) expression in human gingival fibroblasts
102. The transcription factor C/EBPβ is essential for inducible expression of the cox-2 gene in macrophages but not in fibroblasts
103. Redundancy in the signaling pathways and promoter elements regulating cyclooxygenase-2 gene expression in endotoxin-treated macrophage/monocytic cells
104. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation